FMC Secures EU Nod for Isoflex Active Herbicide Market Expansion

08.04.26 14:05 Uhr

Werte in diesem Artikel
Aktien

11,55 EUR 0,10 EUR 0,83%

37,45 EUR 0,31 EUR 0,83%

Indizes

PKT PKT

2.080,0 PKT -2,0 PKT -0,09%

2.129,2 PKT -4,9 PKT -0,23%

24.283,0 PKT -55,7 PKT -0,23%

8.910,1 PKT -20,0 PKT -0,22%

1.909,1 PKT -3,4 PKT -0,18%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

217,6 PKT 1,9 PKT 0,86%

633,1 PKT -1,7 PKT -0,27%

12.905,6 PKT -23,9 PKT -0,18%

24.316,5 PKT -120,5 PKT -0,49%

24.305,6 PKT -79,5 PKT -0,33%

9.416,8 PKT -17,1 PKT -0,18%

17.242,5 PKT -138,5 PKT -0,80%

1.854,4 PKT -8,4 PKT -0,45%

FMC Corporation FMC has secured the European Union’s (“EU”) approval for its Isoflex active herbicide, marking a major regulatory and strategic milestone as it prepares to enter a constrained European crop protection market.  The approval enables FMC to target more than 55 million planted hectares of key crops, such as cereals, corn, oilseed rape and potatoes in the EU, with commercial launches of products with Isoflex active expected from 2027, pending regulatory decisions. This development is particularly significant as it addresses a critical gap in Europe, where growers have lost access to more than 20 herbicide active ingredients since 2019. It left farmers with limited options amid rising herbicide resistance.  Isoflex active, classified as a Group 13 herbicide by the Herbicide Resistance Action Committee, offers a novel mode of action along with broad-spectrum weed control, residual activity and flexible application timing, making it a valuable tool for resistance management and sustainable farming practices.  The product has already been deployed in multiple global markets, including Latin America, Asia and Australia. The EU approval strengthens FMC’s innovation-driven growth strategy, positioning Isoflex as a potential long-term revenue driver and reinforcing the company’s presence in high-value agricultural markets. Shares of FMC are down 52.7% over the past year against the industry’s 33.5% growth. Image Source: Zacks Investment ResearchFMC’s Zacks Rank & Key PicksFMC currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the Consumer Staples space are Archer Daniels Midland Company ADM, Adecoagro S.A. AGRO and Corteva, Inc. CTVA. ADM sports a Zacks Rank of #1 (Strong Buy), while AGRO and CTVA have a Zacks Rank of #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for ADM’s current-year earnings stands at $4.32 per share, implying a 25.9% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 3.8%. The Zacks Consensus Estimate for AGRO’s current-year earnings is pegged at $1.39 per share, indicating a 872.2% year-over-year increase. Shares of AGRO have risen 38.9% over the past year.The Zacks Consensus Estimate for CTVA’s current-year earnings is pegged at $3.63 per share, indicating a 8.7% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 26%.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: FMC und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Fresenius Medical Care (FMC) St.

Analysen zu Fresenius Medical Care (FMC) St.

DatumRatingAnalyst
08.05.2026Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.
08.05.2026Fresenius Medical Care (FMC) St KaufenDZ BANK
07.05.2026Fresenius Medical Care (FMC) St Equal WeightBarclays Capital
06.05.2026Fresenius Medical Care (FMC) St NeutralGoldman Sachs Group Inc.
06.05.2026Fresenius Medical Care (FMC) St HoldDeutsche Bank AG
DatumRatingAnalyst
08.05.2026Fresenius Medical Care (FMC) St KaufenDZ BANK
13.03.2026Fresenius Medical Care (FMC) St KaufenDZ BANK
03.12.2025Fresenius Medical Care (FMC) St BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.11.2025Fresenius Medical Care (FMC) St BuyGoldman Sachs Group Inc.
05.11.2025Fresenius Medical Care (FMC) St KaufenDZ BANK
DatumRatingAnalyst
07.05.2026Fresenius Medical Care (FMC) St Equal WeightBarclays Capital
06.05.2026Fresenius Medical Care (FMC) St NeutralGoldman Sachs Group Inc.
06.05.2026Fresenius Medical Care (FMC) St HoldDeutsche Bank AG
05.05.2026Fresenius Medical Care (FMC) St Equal WeightBarclays Capital
05.05.2026Fresenius Medical Care (FMC) St NeutralGoldman Sachs Group Inc.
DatumRatingAnalyst
08.05.2026Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.
06.05.2026Fresenius Medical Care (FMC) St SellUBS AG
06.05.2026Fresenius Medical Care (FMC) St UnderweightJP Morgan Chase & Co.
05.05.2026Fresenius Medical Care (FMC) St UnderweightJP Morgan Chase & Co.
05.05.2026Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius Medical Care (FMC) St. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen